HK56094A - Optical isomer of an imidazole derivative - Google Patents

Optical isomer of an imidazole derivative Download PDF

Info

Publication number
HK56094A
HK56094A HK56094A HK56094A HK56094A HK 56094 A HK56094 A HK 56094A HK 56094 A HK56094 A HK 56094A HK 56094 A HK56094 A HK 56094A HK 56094 A HK56094 A HK 56094A
Authority
HK
Hong Kong
Prior art keywords
medetomidine
enantiomer
mixture
compounds
acid
Prior art date
Application number
HK56094A
Other languages
German (de)
English (en)
French (fr)
Inventor
Johannes Karjalainen Arto
Einarl Virtanen Raimo
Juhani Savolainen Eino
Original Assignee
Orion-Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10620775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK56094(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion-Yhtyma Oy filed Critical Orion-Yhtyma Oy
Publication of HK56094A publication Critical patent/HK56094A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK56094A 1987-07-16 1994-05-24 Optical isomer of an imidazole derivative HK56094A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8716803A GB2206880B (en) 1987-07-16 1987-07-16 Optical isomers of an imidazole derivative

Publications (1)

Publication Number Publication Date
HK56094A true HK56094A (en) 1994-06-03

Family

ID=10620775

Family Applications (1)

Application Number Title Priority Date Filing Date
HK56094A HK56094A (en) 1987-07-16 1994-05-24 Optical isomer of an imidazole derivative

Country Status (29)

Country Link
US (1) US4910214A (cg-RX-API-DMAC7.html)
EP (1) EP0300652B1 (cg-RX-API-DMAC7.html)
JP (1) JPH0625138B2 (cg-RX-API-DMAC7.html)
KR (1) KR940007311B1 (cg-RX-API-DMAC7.html)
CN (1) CN1022323C (cg-RX-API-DMAC7.html)
AT (1) ATE71941T1 (cg-RX-API-DMAC7.html)
AU (1) AU600839B2 (cg-RX-API-DMAC7.html)
BG (1) BG60473B2 (cg-RX-API-DMAC7.html)
CA (1) CA1337659C (cg-RX-API-DMAC7.html)
CY (2) CY1787A (cg-RX-API-DMAC7.html)
DD (1) DD281807A5 (cg-RX-API-DMAC7.html)
DE (2) DE10399005I2 (cg-RX-API-DMAC7.html)
DK (1) DK165788C (cg-RX-API-DMAC7.html)
ES (1) ES2038757T3 (cg-RX-API-DMAC7.html)
FI (1) FI95375C (cg-RX-API-DMAC7.html)
GB (1) GB2206880B (cg-RX-API-DMAC7.html)
GR (1) GR3003878T3 (cg-RX-API-DMAC7.html)
HK (1) HK56094A (cg-RX-API-DMAC7.html)
HU (1) HU198693B (cg-RX-API-DMAC7.html)
IE (1) IE60456B1 (cg-RX-API-DMAC7.html)
IL (1) IL87076A0 (cg-RX-API-DMAC7.html)
LU (1) LU91010I2 (cg-RX-API-DMAC7.html)
NL (1) NL300117I2 (cg-RX-API-DMAC7.html)
NO (2) NO170579C (cg-RX-API-DMAC7.html)
NZ (1) NZ225362A (cg-RX-API-DMAC7.html)
PT (1) PT88013B (cg-RX-API-DMAC7.html)
SU (1) SU1648248A3 (cg-RX-API-DMAC7.html)
UA (1) UA5560A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA885134B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
IN187238B (cg-RX-API-DMAC7.html) * 1995-06-30 2002-03-09 Astra Ab
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
NZ518447A (en) 1999-10-29 2004-10-29 Orion Corp Treatment or prevention of hypotension and shock
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
ES2396039T3 (es) 2006-03-16 2013-02-18 Tris Pharma, Inc. Formulaciones de liberación modificada que contienen complejos de fármaco-resina de intercambio iónico
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
EP2370136A4 (en) * 2008-12-01 2015-12-30 Map Pharmaceuticals Inc INHALATIVE RELEASE PROCEDURES AND DEVICES
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US20110021588A1 (en) * 2009-05-15 2011-01-27 Recro Pharma, Inc. Sublingual dexmeditomidine compositions and methods of use thereof
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
CN102464619A (zh) * 2010-11-17 2012-05-23 桑迪亚医药技术（上海）有限责任公司 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013069025A1 (en) 2011-11-11 2013-05-16 Neon Laboratories Ltd. "process for the preparation of dexmedetomidine"
SG10201604653TA (en) 2011-12-11 2016-07-28 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ITMI20120311A1 (it) * 2012-02-29 2013-08-30 Edmond Pharma Srl Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
WO2014028610A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
KR102146690B1 (ko) 2012-10-15 2020-08-24 오리온 코포레이션 수의학적 소음 혐오증 완화 방법
EP3054935B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
CN105175339B (zh) * 2015-10-09 2018-01-16 辰欣药业股份有限公司 一种制备盐酸右美托咪定的方法
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
FR3054218B1 (fr) * 2016-07-22 2020-03-06 Universite De Rouen Procede de dedoublement de sels de baclofene
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN115197149B (zh) * 2021-04-02 2023-09-22 四川大学华西医院 一种5-苄基咪唑类化合物及其制备方法和用途
CN114671811A (zh) * 2022-04-14 2022-06-28 南京正科医药股份有限公司 一种右美托咪定拆分副产物的外消旋化回收方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
DE3531682A1 (de) * 1985-09-05 1987-03-12 Thomae Gmbh Dr K (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel

Also Published As

Publication number Publication date
DE10399005I1 (de) 2003-06-05
DK165788C (da) 1993-06-14
ATE71941T1 (de) 1992-02-15
FI95375B (fi) 1995-10-13
NO883155L (no) 1989-01-17
LU91010I2 (fr) 2003-06-19
NL300117I1 (nl) 2003-05-01
CN1030576A (zh) 1989-01-25
ES2038757T3 (es) 1993-08-01
PT88013A (pt) 1989-06-30
NO170579B (no) 1992-07-27
AU1894188A (en) 1989-01-19
JPS6434968A (en) 1989-02-06
IE60456B1 (en) 1994-07-13
FI882819A0 (fi) 1988-06-14
DE3867945D1 (de) 1992-03-05
DK165788B (da) 1993-01-18
GB2206880A (en) 1989-01-18
ZA885134B (en) 1989-04-26
NL300117I2 (nl) 2003-10-01
DK386288D0 (da) 1988-07-11
FI95375C (fi) 1996-01-25
UA5560A1 (uk) 1994-12-28
CY1787A (en) 1995-10-20
IE882174L (en) 1989-01-16
GB2206880B (en) 1991-04-24
CY2004006I1 (el) 2009-11-04
CA1337659C (en) 1995-11-28
GB8716803D0 (en) 1987-08-19
HUT48218A (en) 1989-05-29
FI882819L (fi) 1989-01-17
NO170579C (no) 1992-11-04
SU1648248A3 (ru) 1991-05-07
KR890002030A (ko) 1989-04-07
DE10399005I2 (de) 2012-06-06
GR3003878T3 (cg-RX-API-DMAC7.html) 1993-03-16
NZ225362A (en) 1990-07-26
NO883155D0 (no) 1988-07-15
CN1022323C (zh) 1993-10-06
NO2003004I2 (no) 2005-03-21
CY2004006I2 (el) 2009-11-04
JPH0625138B2 (ja) 1994-04-06
KR940007311B1 (ko) 1994-08-12
DK386288A (da) 1989-01-17
PT88013B (pt) 1995-03-01
BG60473B2 (bg) 1995-04-28
US4910214A (en) 1990-03-20
IL87076A0 (en) 1988-12-30
EP0300652B1 (en) 1992-01-22
DD281807A5 (de) 1990-08-22
EP0300652A1 (en) 1989-01-25
HU198693B (en) 1989-11-28
AU600839B2 (en) 1990-08-23

Similar Documents

Publication Publication Date Title
EP0300652B1 (en) Optical isomer of an imidazole derivative
CA1259995A (en) Adrenergic amidines
EP0125783B1 (en) Dopamine-beta-hydroxylase inhibitors
US4818764A (en) Imidazoline derivative and method of treating depression therewith
RU2120440C1 (ru) Замещенные имидазолы, способы их получения, фармацевтическая композиция на их основе и способ лечения
EP0238281B1 (en) Selective alpha-adrenergic receptor antagonists
FI67544C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefullt imidazolinderivat
Doxey et al. Evidence for pharmacological similarity between alpha 2-adrenoceptors in the vas deferens and central nervous system of the rat
Carlström et al. Molecular characteristics of biogenic monoamines and their analogs
SU1217257A3 (ru) Способ получени производных имидазолина или их нетоксичных солей
US5102914A (en) Antihypertensive sulfonanilides
US6172097B1 (en) Spiro imidazoline compounds
US4318909A (en) Benzoxazocines
Cannon et al. Catechol derivatives of 6-aminobenzocycloheptene: assessment of dopaminergic effects
US4626522A (en) Benzoxazocines intermediates
FR2527208A1 (fr) Isomeres optiques de la (benzodioxanne-1,4 yl-2)-2d-2 imidazoline, leur preparation et leur application en therapeutique
Harrold Part 1: Synthesis of trimetoquinol analogs as potential thromboxane A2 receptor antagonists. Part 2: Synthesis of permanently charged and permanently uncharged dopamine antagonists

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080707